Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

NCT04267120 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Slow enrollment with low accrual

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab
PROCEDURE: Research blood collection

Sponsor

Washington University School of Medicine

Collaborators

[object Object]